Different diets cause alterations in the enteric environment and trigger changes in the expression of hepatic cytochrome P450 3A, a drug-metabolizing enzyme

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 4, 2013, Pages 624-634

  Tajima, Masataka ^a,b   Ikarashi, Nobutomo ^a   Igeta, Shintaro ^a   Toda, Takahiro ^a   Ishii, Makoto ^a   Tanaka, Yoshikazu ^a   Machida, Yoshiaki ^a   Ochiai, Wataru ^a   Yamada, Harumi ^b   Sugiyama, Kiyoshi ^a  

^a HOSHI UNIVERSITY   (Japan)

^b INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Cytochrome P450; High fat diet; Lithocholic acid; Liver

Indexed keywords

CYTOCHROME P450 3A; CYTOCHROME P450 3A11; FAT; LARD; LITHOCHOLIC ACID; MESSENGER RNA; TRIAZOLAM;

ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CALORIC INTAKE; CLOSTRIDIUM SORDELLII; CONTROLLED STUDY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; ENTERIC FEEDING; ENZYME ACTIVITY; FECES; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIPID DIET; LIVER; LIVER WEIGHT; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLIC ACTIVATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PURIFICATION; SMALL INTESTINE; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE LEVEL; WHITE ADIPOSE TISSUE;

ADIPOSE TISSUE, WHITE; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CHOLESTEROL; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DIET, HIGH-FAT; FATTY ACIDS, NONESTERIFIED; FECES; LITHOCHOLIC ACID; LIVER; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED ICR; MICROSOMES; ORGAN SIZE; RNA, MESSENGER; TRIAZOLAM; TRIGLYCERIDES;

EID: 84876940223     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-01005     Document Type: Article

References (52)

1. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. Toxicol., 38, 389-430 (1998).
2. Olinga P, Elferink MG, Draaisma AL, Merema MT, Castell JV, Pérez G, Groothuis GM. Coordinated induction of drug transporters and phase I and II metabolism in human liver slices. Eur. J. Pharm. Sci., 33, 380-389 (2008).
3. Masuyama H, Hiramatsu Y, Kunitomi M, Kudo T, MacDonald PN. Endocrine disrupting chemicals, phthalic acid and nonylphenol, activate Pregnane X receptor-mediated transcription. Mol. Endocrinol., 14, 421-428 (2000).
4. Toda T, Ohi K, Kudo T, Yoshida T, Ikarashi N, Ito K, Sugiyama K. Antibiotics suppress Cyp3a in the mouse liver by reducing lithocholic acid-producing intestinal flora. Yakugaku Zasshi, 129, 601-608 (2009).
5. Toda T, Ohi K, Kudo T, Yoshida T, Ikarashi N, Ito K, Sugiyama K. Ciprofloxacin suppresses Cyp3a in mouse liver by reducing lithocholic acid-producing intestinal flora. Drug Metab. Pharmacokinet., 24, 201-208 (2009).
6. Toda T, Saito N, Ikarashi N, Ito K, Yamamoto M, Ishige A, Watanabe K, Sugiyama K. Intestinal flora induces the expression of Cyp3a in the mouse liver. Xenobiotica, 39, 323-334 (2009).
7. Audet-Walsh E, Auclair-Vincent S, Anderson A. Glucocorticoids and phenobarbital induce murine CYP2B genes by independent mechanisms. Expert Opin. Drug Metab. Toxicol., 5, 1501-1511 (2009).
8. Thangavel C, Boopathi E, Shapiro BH. Intrinsic sexually dimorphic expression of the principal human CYP3A4 correlated with suboptimal activation of GH/glucocorticoid-dependent transcriptional pathways in men. Endocrinology, 152, 4813-4824 (2011).
9. Kudo T, Shimada T, Toda T, Igeta S, Suzuki W, Ikarashi N, Ochiai W, Ito K, Aburada M, Sugiyama K. Altered expression of CYP in TSOD mice: a model of type 2 diabetes and obesity. Xenobiotica, 39, 889-902 (2009).
10. Kudo T, Toda T, Ushiki T, Ohi K, Ikarashi N, Ochiai W, Sugiyama K. Differences in the pharmacokinetics of Cyp3a substrates in TSOD and streptozotocin-induced diabetic mice. Xenobiotica, 40, 282-290 (2010).
11. Brunner LJ, Bai S. Effect of dietary oil intake on hepatic cytochrome P450 activity in the rat. J. Pharm. Sci., 89, 1022-1027 (2000).
12. Finn RD, Henderson CJ, Scott CL, Wolf CR. Unsaturated fatty acid regulation of cytochrome P450 expression via a CAR-dependent pathway. Biochem. J., 417, 43-54 (2009).
13. Landes N, Pfluger P, Kluth D, Birringer M, Rühl R, Böl GF, Glatt H, Brigelius-Flohé R. Vitamin E activates gene expression via the pregnane X receptor. Biochem. Pharmacol., 65, 269-273 (2003).
14. Wang K, Chen S, Xie W, Wan YJ. Retinoids induce cytochrome P450 3A4 through RXR/VDR-mediated pathway. Biochem. Pharmacol., 75, 2204-2213 (2008).
15. Misra A, Singhal N, Khurana L. Obesity, the metabolic syndrome, and type 2 diabetes in developing countries: role of dietary fats and oils. J. Am. Coll. Nutr., 29 (Suppl.), 289S-301S (2010).
16. Do GM, Oh HY, Kwon EY, Cho YY, Shin SK, Park HJ, Jeon SM, Kim E, Hur CG, Park TS, Sung MK, McGregor RA, Choi MS. Long-term adaptation of global transcription and metabolism in the liver of high-fat diet-fed C57BL/6J mice. Mol. Nutr. Food Res., 55 (Suppl. 2), S173-S185 (2011).
17. Nishikawa S, Sugimoto J, Okada M, Sakairi T, Takagi S. Gene expression in livers of BALB/C and C57BL/6J mice fed a high-fat diet. Toxicol. Pathol., 40, 71-82 (2012).
18. Koide CL, Collier AC, Berry MJ, Panee J. The effect of bamboo extract on hepatic biotransforming enzymes - Findings from an obese-diabetic mouse model. J. Ethnopharmacol., 133, 37-45 (2011).
19. Yao HT, Lii CK, Chou RH, Lin JH, Yang HT, Chiang MT. Effect of chitosan on hepatic drug-metabolizing enzymes and oxidative stress in rats fed low- and high-fat diets. J. Agric. Food Chem., 58, 5187-5193 (2010).
20. Yoshinari K, Takagi S, Yoshimasa T, Sugatani J, Miwa M. Hepatic CYP3A expression is attenuated in obese mice fed a high-fat diet. Pharm. Res., 23, 1188-1200 (2006).
21. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193, 265-275 (1951).
22. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227, 680-685 (1970).
23. Perloff MD, von Moltke LL, Court MH, Kotegawa T, Shader RI, Greenblatt DJ. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. J. Pharmacol. Exp. Ther., 292, 618-628 (2000).
24. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. A pharmacokinetic analysis program (multi) for microcomputer. J. Pharmacobiodyn., 4, 879-885 (1981).
25. Nakashima K, Yamamoto K, Al-Dirbashi OY, Nakashima MN. Disposition of triazolam in the rat by brain microdialysis and semimicro column high-performance liquid chromatography with UV absorbance detection. Biomed. Chromatogr., 16, 219-223 (2002).
26. Ikarashi N, Kagami M, Kobayashi Y, Ishii M, Toda T, Ochiai W, Sugiyama K. Changes in the pharmacokinetics of digoxin in polyuria in streptozotocin- induced diabetic mice and lithium carbonate-treated mice. Xenobiotica, 41, 486-493 (2011).
27. Eyssen HJ, Parmentier GG, Mertens JA. Sulfate bile acids in germ-free and conventional mice. Eur. J. Biochem., 66, 507-514 (1976).
28. Yamaguchi M, Matsunaga R, Fukuda K, Nakamura M, Ohkura Y. Highly sensitive determination of free polyunsaturated, long-chain fatty acids in human serum by high-performance liquid chromatography with fluorescence detection. Anal. Biochem., 155, 256-261 (1986).
29. Yamaguchi M, Matsunaga R, Hara S, Nakamura M, Ohkura Y. Highly sensitive determination of free fatty acids in human serum by high-performance liquid chromatography with fluorescence detection. J. Chromatogr. A, 375, 27-35 (1986).
30. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm. Res., 16, 408-414 (1999).
31. Wang E, Lew K, Barecki M, Casciano CN, Clement RP, Johnson WW. Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4. Chem. Res. Toxicol., 14, 1596-1603 (2001).
32. Perloff MD, von Moltke LL, Cotreau MM, Greenblatt DJ. Unchanged cytochrome P450 3A (CYP3A) expression and metabolism of midazolam, triazolam, and dexamethasone in mdr(-/-) mouse liver microsomes. Biochem. Pharmacol., 57, 1227-1232 (1999).
33. Schrag ML, Wienkers LC. Triazolam substrate inhibition: evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site. Drug Metab. Dispos., 29, 70-75 (2001).
34. Sidhu S, Malhotra S, Garg SK. Influence of high fat diet (butter) on pharmacokinetics of phenytoin and carbamazepine. Methods Find. Exp. Clin. Pharmacol., 26, 634-638 (2004).
35. Tan KK, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB. Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients. Clin. Pharmacol. Ther., 57, 425-433 (1995).
36. Kang HJ, Song IS, Lee SS, Yoo MA, Shin JG. Effects of dietary salt on the expression of drug transporters, cytochrome P4503a, and nuclear receptors in rats. Xenobiotica, 38, 147-155 (2008).
37. Peters LP, Teel RW. Effects of high sucrose diet on body and liver weight and hepatic enzyme content and activity in the rat. In Vivo, 17, 61-65 (2003).
38. van Waterschoot RA, Rooswinkel RW, Wagenaar E, van der Kruijssen CM, van Herwaarden AE, Schinkel AH. Intestinal cytochrome P450 3A plays an important role in the regulation of detoxifying systems in the liver. FASEB J., 23, 224-231 (2009).
39. Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, Liu Y, Klaassen CD, Brown KK, Reinhard J, Willson TM, Koller BH, Kliewer SA. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl. Acad. Sci. U.S.A., 98, 3369-3374 (2001).
40. Xie W, Radominska-Pandya A, Shi Y, Simon CM, Nelson MC, Ong ES, Waxman DJ, Evans RM. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc. Natl. Acad. Sci. U.S.A., 98, 3375-3380 (2001).
41. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD, Lehmann JM. Bile acids: natural ligands for an orphan nuclear receptor. Science, 284, 1365-1368 (1999).
42. Yu J, Lo JL, Huang L, Zhao A, Metzger E, Adams A, Meinke PT, Wright SD, Cui J. Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J. Biol. Chem., 277, 31441-31447 (2002).
43. Han S, Li T, Ellis E, Strom S, Chiang JY. A novel bile acid-activated vitamin D receptor signaling in human hepatocytes. Mol. Endocrinol., 24, 1151-1164 (2010).
44. Matsubara T, Yoshinari K, Aoyama K, Sugawara M, Sekiya Y, Nagata K, Yamazoe Y. Role of vitamin D receptor in the lithocholic acid-mediated CYP3A induction in vitro and in vivo. Drug Metab. Dispos., 36, 2058-2063 (2008).
45. Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J. Lipid Res., 47, 241-259 (2006).
46. Gibson GR. Dietary modulation of the human gut microflora using prebiotics. Br. J. Nutr., 80, S209-S212 (1998).
47. Goldin B, Gorbach SL. Alterations in fecal microflora enzymes related to diet, age, lactobacillus supplements, and dimethylhydrazine. Cancer, 40 (Suppl.), 2421-2426 (1977).
48. Hawrelak JA, Myers SP. The causes of intestinal dysbiosis: a review. Altern. Med. Rev., 9, 180-197 (2004).
49. Villalon L, Tuchweber B, Yousef IM. Effect of a low protein diet on bile flow and composition in rats. J. Nutr., 117, 678-683 (1987).
50. Wu J, Peng SS. Comparison of hypolipidemic effect of refined konjac meal with several common dietary fibers and their mechanisms of action. Biomed. Environ. Sci., 10, 27-37 (1997).
51. Khan AA, Chow EC, Porte RJ, Pang KS, Groothuis GM. The role of lithocholic acid in the regulation of bile acid detoxication, synthesis, and transport proteins in rat and human intestine and liver slices. Toxicol. In Vitro, 25, 80-90 (2011).
52. Varel VH, Bryant MP. Nutritional features of Bacteroides fragilis subsp. fragilis. Appl. Microbiol., 28, 251-257 (1974).